Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
Colorcon
Medtronic
Dow

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR IMODIUM MULTI-SYMPTOM RELIEF


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Imodium Multi-symptom Relief

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075868 ↗ Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed National Cancer Institute (NCI) Phase 3 2003-12-01 RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00075868 ↗ Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed Radiation Therapy Oncology Group Phase 3 2003-12-01 RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00292344 ↗ Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Completed Bausch Health Americas, Inc. Phase 4 2004-06-01 Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
NCT00292344 ↗ Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Completed Valeant Pharmaceuticals International, Inc. Phase 4 2004-06-01 Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imodium Multi-symptom Relief

Condition Name

Condition Name for Imodium Multi-symptom Relief
Intervention Trials
Diarrhea 5
Fecal Incontinence 3
Travelers' Diarrhea 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Imodium Multi-symptom Relief
Intervention Trials
Diarrhea 10
Fecal Incontinence 3
Rectal Neoplasms 2
Dysentery 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imodium Multi-symptom Relief

Trials by Country

Trials by Country for Imodium Multi-symptom Relief
Location Trials
United States 59
Mexico 6
India 1
Kenya 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Imodium Multi-symptom Relief
Location Trials
California 5
Texas 5
North Carolina 4
Maryland 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imodium Multi-symptom Relief

Clinical Trial Phase

Clinical Trial Phase for Imodium Multi-symptom Relief
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Imodium Multi-symptom Relief
Clinical Trial Phase Trials
Completed 12
Terminated 5
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imodium Multi-symptom Relief

Sponsor Name

Sponsor Name for Imodium Multi-symptom Relief
Sponsor Trials
M.D. Anderson Cancer Center 2
Johnson & Johnson Consumer and Personal Products Worldwide 2
McNeil AB 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Imodium Multi-symptom Relief
Sponsor Trials
Other 28
Industry 17
U.S. Fed 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Baxter
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.